Evidence map›Paper›PMID 35988330›Full record

ArticleMultiple sclerosis and related disorders2022

Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis.

E Tavazzi, G Della Porta, F S Robustelli Della Cuna, L Gervasio, E Guerra, M A Tejada Condemayta, A Filosa, C Montomoli, R Bergamaschi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

E TavazziMultiple Sclerosis Centre, IRCCS Mondino Foundation, Via Mondino 2, Pavia 27100, Italy. Electronic address: eleonora.tavazzi@mondino.it.
G Della PortaMultiple Sclerosis Centre, IRCCS Mondino Foundation, Via Mondino 2, Pavia 27100, Italy.
F S Robustelli Della CunaDepartment of Drug Sciences, University of Pavia, Pavia, Italy; Pharmacy Service, IRCCS Mondino Foundation, Pavia, Italy.
L GervasioPharmacy Service, IRCCS Mondino Foundation, Pavia, Italy.
E GuerraDepartment of Drug Sciences, University of Pavia, Pavia, Italy.
M A Tejada CondemaytaMultiple Sclerosis Centre, IRCCS Mondino Foundation, Via Mondino 2, Pavia 27100, Italy.
A FilosaDepartment of Public Health, Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, Pavia, Italy.
C MontomoliDepartment of Public Health, Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, Pavia, Italy.
R BergamaschiMultiple Sclerosis Centre, IRCCS Mondino Foundation, Via Mondino 2, Pavia 27100, Italy.
University of Pavia · ITFoundation Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFew data are available on adverse events (AE) associated to vaccines in persons with multiple sclerosis (pwMS).

aimsto study the incidence of acute phase AE (AP-AE) related to SARS-CoV-2 mRNA vaccines in pwMS compared to a control group, and to analyze the association between AP-AE and disease modifying treatments (DMT).

methodsThis was a cross-sectional study on 438 PwMS and 481 age- and sex-matched subjects not affected by dysimmune diseases that underwent two doses of SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer/BioNtech).

resultsTwo hundred and twenty five (51.4%) pwMS complained of ≥1 AP-AE after the first dose, 269 (61.4%) after the second dose. A logistic regression analysis revealed that only pwMS on Fingolimod and Ocrelizumab did not show a higher risk of developing AP-AE. The likelihood to present with ≥1 AP-AE, after correcting for age and sex, was significantly higher in pwMS than controls.

conclusionsThis study reports qualitative and quantitative features of AP-AE associated with the first and second doses of SARS-CoV-2 vaccine in a large sample of pwMS. The only risk factor identified for developing AP-AE is female gender. AntiCD-20 monoclonal antibodies and S1P inhibitors are associated with a lower risk of AP-AE occurrence.

Indexed as

COVID-19COVID-19 VaccinesMultiple SclerosisBNT162 VaccineCross-Sectional StudiesFemaleHumansRisk FactorsSARS-CoV-2VaccinationBNT162 VaccineCOVID-19 VaccinesAdverse eventsCOVIDDisease modifying treatmentsMultiple sclerosisSARS-CoV-2Vaccines

Identifiers

PMID35988330
PMCPMC9376979
OpenAlexW4291595142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.